TP53 and triple-negative breast carcinoma: This was demonstrated in a study by Hu et al. where a significantly increased frequency of mutations to the PIK3CA, TP53, NOTCH2, MLL3, and SETD2 genes was seen in triple-negative breast cancer patients exhibiting drug resistance following 3 months of chemotherapy [35].